Unsupervised clustering identifies three blood immune endophenotypes associated with distinct multiple-sclerosis trajectories
In two multicenter longitudinal cohorts of early multiple sclerosis (discovery n=309; validation n=232), unsupervised clustering of high-dimensional flow-cytometry and serum-proteomics profiles identified three peripheral-blood immune endophenotypes. Follow-up associated the groups with different trajectories of inflammation versus early structural damage. In the endophenotype-3 subgroup, patients subsequently treated with interferon beta had higher four-year progression and MRI activity than patients receiving other therapies.
Technology: Unsupervised clustering of high-dimensional flow-cytometry and serum-proteomics profiles (the reviewed abstract does not name the clustering algorithm)
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: retrospective or benchmark
- Tested: In two multicenter longitudinal cohorts of early multiple sclerosis (discovery n=309; validation n=232), unsupervised clustering of high-dimensional flow-cytometry and serum-proteomics profiles identified three peripheral-blood immune endophenotypes.
- Still unknown: The source reports cohort associations, not randomized treatment effects. The higher progression and MRI activity among endophenotype-3 patients treated with interferon beta may be affected by treatment selection and other confounding; it does not establish that interferon beta caused worse outcomes or that the signature can guide care. The validation cohort is an independent patient cohort within the study, not independent replication by another research group. The reviewed abstract does not provide the clustering algorithm name or establish prospective clinical utility.
- AI role: The researchers combined flow-cytometry immune measurements and serum-protein profiles, then used unsupervised clustering to define three immune endophenotypes in the discovery cohort and assess them in an independent multicenter validation cohort. The clustering generated the patient groups whose longitudinal clinical and paraclinical trajectories were compared; the repository abstract does not specify the algorithm name.
Evidence sources: https://edoc.mdc-berlin.de/id/eprint/24233/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 55 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.